The phosphatidylinositol 3-kinase (PI3K) pathway is frequently activated in breast cancers due to (i) amplification of ERBB2, an oncogene that stimulates the PI3K pathway and (ii) activating mutations of the PI3K catalytic subunit, PIK3CA (Koboldt et al., 2012). This evidence concerns the gene ERBB2 and breast cancer.